Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

News SummaryMost relevantAll newsSector newsTweets 

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2012 | 10:20pm CET

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics

SOURCE Halozyme Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
02/13 MABVAX THERAPEUTICS : Studies Lead Investigational Drug MVT-5873 with Halozyme P..
02/01 HALOZYME THERAPEUTICS : To Host Fourth Quarter 2016 Financial Results Conference..
01/12 HALOZYME THERAPEUTICS : Announces Phase 2 Study In Advanced Pancreas Cancer Meet..
01/10 HALOZYME THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and E..
01/09 HALOZYME THERAPEUTICS INC : Results of Operations and Financial Condition, Regul..
01/09 HALOZYME THERAPEUTICS : Provides Program Updates, 2017 Financial Guidance At 35t..
01/09 HALOZYME THERAPEUTICS, INC. : Biotech Industry Off to a Strong Start in 2017 Lat..
01/05 HALOZYME THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (for..
01/05 HALOZYME THERAPEUTICS : Announces Phase 2 Study In Advanced Pancreas Cancer Meet..
2016 HALOZYME THERAPEUTICS : To Present At The 35th Annual J.P. Morgan Healthcare Con..
More news
Sector news : Bio Therapeutic Drugs
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02/13 MabVax's MVT-5873 shows encouraging action in preclinical pancreatic cancer m..
01/24 Pancreatic Cancer Field Awaits Sparse Data
01/09 Halozyme down 5.9% after hours on 2017 guidance
01/06 Trump Rally Took A Break - Cramer's Mad Money (1/5/17)
01/05 Midday Gainers / Losers